LDL Cholesterol to Apolipoprotein B Ratio

When LDL/ApoB Ratio is LOW (below 1.0, small dense LDL pattern)

A low LDL/ApoB ratio indicates that each LDL particle carries less cholesterol than average, meaning there are more LDL particles per unit of LDL cholesterol measured. This is the hallmark of small dense LDL (sdLDL, pattern B), a phenotype associated with 3-fold greater cardiovascular risk compared to large buoyant LDL at the same LDL-C level. Small dense LDL particles have lower affinity for hepatic LDL receptors (prolonged circulation time), higher susceptibility to oxidative modification, and greater penetration of the arterial wall endothelium. This pattern arises when triglycerides exceed 1.5-2.0 mmol/L and HDL falls below 1.0 mmol/L, conditions that activate CETP-mediated lipid exchange.

A ratio below 1.0 should prompt aggressive management even if LDL appears borderline elevated. Standard LDL targets underestimate cardiovascular risk in this setting; ApoB targets become the primary guide. Target ApoB below 0.9 g/L for primary prevention, below 0.7 g/L for high-risk individuals including active PED users with multiple cardiovascular risk factors.

Management steps:

• Omega-3 (EPA/DHA) -- 3-4g/day: reduces triglycerides and CETP activity, shifting LDL distribution toward larger, less dense particles
• Niacin (Extended-Release) -- 1000-2000mg/day: raises HDL, lowers triglycerides, and directly increases LDL particle size (most effective supplement for improving sdLDL)
• Berberine -- 500mg 2-3x/day: reduces triglycerides and improves insulin sensitivity, addressing root cause of sdLDL pattern
• Reduce refined carbohydrates and fructose: carbohydrate-driven hypertriglyceridaemia is the primary driver of sdLDL pattern
• Increase monounsaturated fats (olive oil, avocado): improve overall lipoprotein quality
• Aerobic exercise 30-45 min, 4-5x/week: raises HDL and reduces triglycerides, correcting both drivers of the sdLDL phenotype

PED-Specific Considerations: Oral AAS compounds activate hepatic triglyceride lipase and suppress LPL, both of which promote LDL remodelling toward smaller, denser particles. This effect is most pronounced with stanozolol, oxandrolone, and oxymetholone. Injectable testosterone at TRT doses causes a modest shift toward sdLDL only at higher doses or when triglycerides are already elevated. Trenbolone acetate produces a particularly unfavourable LDL particle pattern due to its strong androgen receptor agonism in the liver. Monitoring ApoB alongside LDL and calculating this ratio provides a more complete picture of atherogenic burden on cycle than LDL alone.

When LDL/ApoB Ratio is HIGH (above 1.4, large buoyant LDL pattern)

A high ratio indicates predominantly large buoyant LDL particles (pattern A). This is the desired finding. While not a risk-free state, large buoyant LDL carries significantly lower cardiovascular risk per particle. If ApoB is within target range alongside a high LDL/ApoB ratio, the elevated LDL-C is less concerning from an atherogenicity standpoint.

PED-Specific Considerations: Some natural athletes and TRT users with low-dose testosterone and excellent metabolic health maintain a high LDL/ApoB ratio even with modestly elevated LDL. This contextualises the LDL result as predominantly low-risk large buoyant particles. However, ApoB should still be used as the primary therapeutic target, as it remains the most accurate measure of atherogenic particle burden regardless of particle size distribution.

References:

• Lamarche, B., Tchernof, A., Moorjani, S., et al. (1997). Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Circulation, 95(1), 69-75. DOI: 10.1161/01.cir.95.1.69
• Berneis, K. K., & Krauss, R. M. (2002). Metabolic origins and clinical significance of LDL heterogeneity. Journal of Lipid Research, 43(9), 1363-1379. DOI: 10.1194/jlr.r200004-jlr200
• Hartgens, F., Rietjens, G., Keizer, H. A., Kuipers, H., & Wolffenbuttel, B. H. R. (2004). Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). British Journal of Sports Medicine, 38(3), 253-259. DOI: 10.1136/bjsm.2003.000199
• Grundy, S. M., Stone, N. J., Bailey, A. L., et al. (2019). 2018 AHA/ACC guideline on the management of blood cholesterol. Journal of the American College of Cardiology, 73(24), e285-e350. DOI: 10.1016/j.jacc.2018.11.003